FDA Authorizes At-Home Initiation of Subcutaneous Leqembi for Alzheimer's

The U.S. Food and Drug Administration has approved a new starting dosage regimen for the subcutaneous formulation of Leqembi, an Alzheimer's disease treatment. This approval allows for the initial dose to be administered at home, potentially enhancing patient access and convenience. Leqembi is an amyloid beta-directed antibody for adult patients.